Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Sarcoma, Ewing 2Osteosarcoma 2Rhabdoid Tumor 1Osteosarcoma Recurrent 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Diffuse Intrinsic Pontine Glioma 1

Interventions

tazemetostat 6X-Rays 6Phantoms, Imaging 6Magnetic Resonance Spectroscopy 6Cyclophosphamide 6Specimen Handling 5Etoposide 5Carboplatin 5etoposide phosphate 4Temozolomide 4Nuclear Medicine Department, Hospital 4Granulocyte Colony-Stimulating Factor 4palbociclib 3Topotecan 3Thiotepa 3Sirolimus 3Mesna 3Melphalan 3Ifosfamide 3Filgrastim 3Busulfan 3Biopsy 3ulixertinib 2tipifarnib 2selpercatinib 2omburtamab I-131 2olaparib 2larotrectinib 2ivosidenib 2fludarabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Rhabdoid Tumor × Eflornithine × Sarcoma × Clear all
NCT06465199 2026-06-03

Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

Milton S. Hershey Medical Center

Phase 1/2 Recruiting
289 enrolled
CNSSarcoma

Diffuse Intrinsic Pontine Glioma, Neuroblastoma, Sarcoma, Ewing, Osteosarcoma, Neuroectodermal Tumors, Primitive, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡